CoChat

ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma

Open access
Krakstad, Camilla, Tangen, Ingvild L., Hoivik, Erling A., Halle, Mari K., Berg, Anna, Werner, Henrica M., Ræder, Maria B., Kusonmano, Kanthida, Zou, June X., Øyan, Anne M., Stefansson, Ingunn, Trovik, Jone, Kalland, Karl-Henning, Chen, Hong-Wu, Salvesen, Helga B. · 2015 · Oncotarget
Cited by 47

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

// Camilla Krakstad 1,2 , Ingvild L. Tangen 1,2 , Erling A. Hoivik 1,2 , Mari K. Halle 1,2 , Anna Berg 1,2 , Henrica M. Werner 1,2 , Maria B. Ræder 1,2 , Kanthida Kusonmano 1,2,3 , June X. Zou 4 , Anne M. Øyan 5,6 , Ingunn Stefansson 5,7 , Jone Trovik 1,2 , Karl-Henning Kalland 5,6 , Hong-Wu Chen 4 and Helga B. Salvesen 1,2 1 Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway 2 Department of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway 3 Computational Biology Unit, University of Bergen, Bergen, Norway 4 Department of Internal Medicine and Department of Biochemistry and Molecular Medicine, UC Davis Comprehensive Cancer Center, University of California, Davis, CA, USA 5 Centre for Cancer Biomarkers, Department of Clinical Medicine, University of Bergen, Bergen, Norway 6 Department of Microbiology, Haukeland University Hospital, Bergen, Norway 7 Department of Pathology, Haukeland University Hospital, Bergen, Norway Correspondence to: Camilla Krakstad, email: // Keywords : endometrial cancer, ATAD2, biomarker, molecular profiling Received : April 07, 2015 Accepted : July 02, 2015 Published : July 22, 2015 Abstract We have explored the potential for clinical implementation of ATAD2 as a biomarker for aggressive endometrial cancer by investigating to what extent immunohistochemical (IHC) staining for ATAD2 is feasible, reflects clinical phenotype and molecular subgroups of endometrial carcinomas. Increased expression of the ATAD2 gene has been implicated in cancer development and progression in a number of tissues, but few studies have investigated ATAD2 expression using IHC. Here we show that high ATAD2 protein expression is significantly associated with established clinical-pathological variables for aggressive endometrial cancer, also in the subset of estrogen receptor α (ERα) positive tumors. Protein and mRNA expression of ATAD2 were highly correlated ( P < 0.001), suggesting that IHC staining may represent a more clinically applicable measure of ATAD2 level in routinely collected formalin fixed paraffin embedded specimens. Gene expression alterations in samples with high ATAD2 expression revealed upregulation of several cancer-related genes (B-MYB, CDCs, E2Fs) and gene sets that previously have been linked to aggressive disease and potential for new targeting therapies. Our results support that IHC staining for ATAD2 may be a clinically applicable biomarker reflecting clinical phenotype and targetable alterations in endometrial carcinomas to be further explored in controlled clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.4955

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 47

Metadata

Authors
Krakstad, C., Tangen, I. L., Hoivik, E. A., Halle, M. K., Berg, A., Werner, H. M., Ræder, M. B., Kusonmano, K., Zou, J. X., Øyan, A. M., Stefansson, I., Trovik, J., Kalland, K.-H., Chen, H.-W., & Salvesen, H. B.
Venue
Oncotarget
Published
2015-07-22
Volume
6
Issue
29
Pages
28440-28452
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1912839783
Cited by
47
References
1
FWCI
5.19
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.